**Core Concept**
Zafirlukast is a type of medication known as a cysteinyl leukotriene receptor antagonist (LTRA). It works by inhibiting the action of cysteinyl leukotrienes, which are potent pro-inflammatory mediators involved in the pathogenesis of asthma and other respiratory diseases.

**Why the Correct Answer is Right**
Zafirlukast specifically targets the cysteinyl leukotriene receptor 1 (CysLT1R), which is the primary receptor for cysteinyl leukotrienes. By blocking this receptor, zafirlukast prevents the binding of cysteinyl leukotrienes to CysLT1R, thereby reducing bronchoconstriction, inflammation, and mucus production in the airways. This mechanism of action makes zafirlukast an effective treatment for asthma and other respiratory conditions.

**Why Each Wrong Option is Incorrect**
* **Option A:** This option is incorrect because zafirlukast does not act by blocking the action of histamine receptors, which are primarily involved in allergic reactions and anaphylaxis.
* **Option B:** This option is incorrect because zafirlukast does not act by inhibiting the enzyme phosphodiesterase (PDE), which is involved in the breakdown of cyclic nucleotides and plays a role in smooth muscle relaxation.
* **Option C:** This option is incorrect because zafirlukast does not act by blocking the action of bradykinin, which is a peptide involved in inflammation and pain.

**Clinical Pearl / High-Yield Fact**
Cysteinyl leukotrienes are produced by the action of 5-lipoxygenase on arachidonic acid, leading to the formation of leukotriene A4 (LTA4), which is then converted to cysteinyl leukotrienes by the enzyme LTA4 hydrolase. This pathway is a key target for LTRA medications like zafirlukast.

**Correct Answer:** C.